Clinical Trial Update: Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing docetaxel/prednisone with and without enzalutamide in castration-resistant prostate cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Enzalutamide (enzalutamide)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Prostate Cancer Clinical Trials Consortium | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-03-12